Bank of New York Mellon’s Corbus Pharmaceuticals CRBP Stock Holding History

Bank of New York Mellon’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$425K	Buy	+45,282	New	+$429K	﹤0.01%	3818
2025 Q2	–	Sell	-23,206	Closed	-$123K	–	4161
2025 Q1	$123K	Sell	23,206 -1	-0%	-$9	﹤0.01%	3973
2024 Q4	$274K	Sell	23,207 -1,069	-4%	-$17.9K	﹤0.01%	3826
2024 Q3	$501K	Sell	24,276 -5,960	-20%	-$305K	﹤0.01%	3517
2024 Q2	$1.37M	Buy	+30,236	New	+$1.27M	﹤0.01%	3010
2023 Q1	–	Sell	-1,069	Closed	-$3.54K	–	4395
2022 Q4	$3.54K	Sell	1,069 -74	-6%	-$285	﹤0.01%	4457
2022 Q3	$5K	Hold	1,143	–	–	﹤0.01%	4535
2022 Q2	$9K	Hold	1,143	–	–	﹤0.01%	4555
2022 Q1	$18K	Hold	1,143	–	–	﹤0.01%	4621
2021 Q4	$21K	Hold	1,143	–	–	﹤0.01%	4582
2021 Q3	$35K	Sell	1,143 -5,431	-83%	-$214K	﹤0.01%	4476
2021 Q2	$361K	Sell	6,574 -2,330	-26%	-$129K	﹤0.01%	3911
2021 Q1	$527K	Buy	8,904 +1,357	+18%	+$89.2K	﹤0.01%	3659
2020 Q4	$282K	Sell	7,547 -1,546	-17%	-$57.8K	﹤0.01%	3853
2020 Q3	$492K	Buy	9,093 +72	+0.8%	+$13K	﹤0.01%	3498
2020 Q2	$2.27M	Buy	9,021 +1,757	+24%	+$355K	﹤0.01%	2607
2020 Q1	$1.14M	Buy	7,264 +624	+9%	+$105K	﹤0.01%	2881
2019 Q4	$1.09M	Buy	6,640 +134	+2%	+$19.8K	﹤0.01%	3202
2019 Q3	$951K	Sell	6,506 -498	-7%	-$86.7K	﹤0.01%	3206
2019 Q2	$1.46M	Buy	7,004 +137	+2%	+$29.3K	﹤0.01%	2991
2019 Q1	$1.43M	Buy	6,867 +388	+6%	+$85.6K	﹤0.01%	2958
2018 Q4	$1.14M	Buy	6,479 +543	+9%	+$108K	﹤0.01%	3034
2018 Q3	$1.34M	Sell	5,936 -321	-5%	-$51.9K	﹤0.01%	3083
2018 Q2	$948K	Sell	6,257 -68	-1%	-$12.4K	﹤0.01%	3274
2018 Q1	$1.16M	Buy	6,325 +6	+0.1%	+$1.35K	﹤0.01%	3135
2017 Q4	$1.35M	Buy	6,319 +1,314	+26%	+$281K	﹤0.01%	3074
2017 Q3	$1.07M	Buy	5,005 +445	+10%	+$87.1K	﹤0.01%	3179
2017 Q2	$862K	Buy	4,560 +3,857	+549%	+$756K	﹤0.01%	3334
2017 Q1	$174K	Buy	703 +50	+8%	+$12.3K	﹤0.01%	3912
2016 Q4	$166K	Sell	653 -110	-14%	-$25.2K	﹤0.01%	3941
2016 Q3	$155K	Buy	+763	New	+$94.9K	﹤0.01%	3948

Other funds holding CRBP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon's CRBP Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Corbus Pharmaceuticals (CRBP) in Q2 2026: 45,282 shares worth $425K. The stake represents ﹤0.01% of the portfolio and ranks #3818 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in CRBP as recently as Q1 2025.

Bank of New York Mellon first reported a position in CRBP in Q3 2016 and has held it in 31 quarters since. The position peaked at $2.27M in Q2 2020. 37 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

Bank of New York Mellon held 45,282 shares of Corbus Pharmaceuticals worth $425K as of Q2 2026.
Corbus Pharmaceuticals was a new Bank of New York Mellon position in Q2 2026.
Corbus Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3818 holding.
Bank of New York Mellon first reported a position in Corbus Pharmaceuticals in Q3 2016 and has held it in 31 quarters since.
Bank of New York Mellon's Corbus Pharmaceuticals position peaked at $2.27M in Q2 2020.
37 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.